Litigation Details for Celltrion Healthcare Co., Ltd. v. Janssen Biotech, Inc. (D. Mass. 2014)

Celltrion Healthcare Co., Ltd. v. Janssen Biotech, Inc. (D. Mass. 2014)

Docket		Date Filed	2014-03-31
Court	District Court, D. Massachusetts	Date Terminated	2014-10-24
Cause	28:1338 Patent Infringement	Assigned To	Mark Lawrence Wolf
Jury Demand	None	Referred To
Patents	7,994,364; 8,163,798; 8,536,130; 8,629,179
Link to Docket	External link to docket

Details for Celltrion Healthcare Co., Ltd. v. Janssen Biotech, Inc. (D. Mass. 2014)

Date Filed	Document No.	Description	Snippet	Link To Document
2014-03-31				External link to document

Celltrion Healthcare v. Janssen Biotech, 1:14-cv-11613: Litigation Summary and Patent Analysis

Last updated: August 7, 2026

Celltrion Healthcare’s declaratory-judgment action against Janssen Biotech concerned Celltrion’s proposed infliximab biosimilar, CT-P13, later marketed in the United States as Inflectra. The case focused on U.S. Patent No. 6,284,471, a Janssen-affiliated patent associated with Remicade and anti-TNF antibody treatment. The District of Massachusetts dismissed the action on jurisdictional grounds before reaching patent validity or infringement. The case therefore produced no merits determination, no enforceability ruling, and no generic or biosimilar launch injunction.

What was Celltrion Healthcare v. Janssen Biotech about?

Celltrion sought a declaration that its proposed infliximab product would not infringe Janssen’s patent and that the patent was invalid or unenforceable. The dispute arose before commercial launch of Celltrion’s U.S. biosimilar version of Remicade.

Item	Detail
Court	U.S. District Court for the District of Massachusetts
Case number	1:14-cv-11613
Plaintiff	Celltrion Healthcare Co., Ltd.
Defendant	Janssen Biotech, Inc.
Reference product	Remicade, infliximab
Proposed biosimilar	CT-P13, later Inflectra
Principal patent	U.S. Patent No. 6,284,471
Action type	Declaratory judgment for noninfringement and invalidity
Procedural result	Dismissed before merits adjudication
Commercial consequence	No injunction or court-ordered delay of Inflectra approval

Celltrion’s complaint was designed to remove patent uncertainty before launch. The company sought a judicial ruling before Janssen filed a conventional infringement action based on the proposed biosimilar.

What patent was at issue in the Celltrion v. Janssen litigation?

The central patent was U.S. Patent No. 6,284,471, generally associated with anti-TNF antibody technology and therapeutic use of infliximab-related antibodies. The patent issued in 2001 and had an expected expiration in 2018, subject to any applicable patent-term adjustment or extension.

The patent was important commercially because Remicade had been approved in 1998 and generated substantial sales across rheumatoid arthritis, Crohn’s disease, ulcerative colitis, psoriasis, psoriatic arthritis, and ankylosing spondylitis indications.

The case did not result in a judicial construction of the disputed claims. The court did not determine whether CT-P13 practiced the patent, whether the patent claims were anticipated or obvious, or whether Janssen could enforce the patent against Celltrion.

Was U.S. Patent No. 6,284,471 an Orange Book patent?

No. Remicade is a biologic, and biologic patent information is not listed in the FDA’s Orange Book in the same manner as patents for small-molecule drugs. The relevant regulatory patent framework is the Biologics Price Competition and Innovation Act, or BPCIA, together with the FDA’s Purple Book and related patent-disclosure procedures.

This distinction matters. A biosimilar applicant does not submit a conventional Abbreviated New Drug Application with a Paragraph IV certification against an Orange Book patent. Instead, the BPCIA establishes a separate exchange of patent information, often called the “patent dance,” followed by potential patent litigation.

Why did the District of Massachusetts dismiss the case?

The court dismissed the action because Celltrion had not established an immediate and concrete case or controversy sufficient for declaratory-judgment jurisdiction. The court did not decide the patent merits.

Celltrion’s position was that it faced a real threat of patent litigation because it intended to obtain FDA approval and commercialize CT-P13. Janssen challenged whether those intentions had created an actual controversy at the time of filing.

The jurisdictional issue turned on the status of Celltrion’s regulatory application and the commercial conditions surrounding the proposed launch. A future biosimilar launch, without a sufficiently immediate infringement threat, was not enough to establish federal jurisdiction under the Declaratory Judgment Act.

The dismissal reflected a timing problem:

1. Celltrion’s product had not yet been approved by the FDA.
2. Commercial marketing had not yet begun.
3. Janssen had not filed an infringement action against Celltrion.
4. The record did not establish an immediate and substantial controversy requiring judicial intervention.

The result was a dismissal without a patent-validity or infringement ruling. The court’s decision therefore did not create binding precedent that either upheld or invalidated the Remicade patent claims.

Did Celltrion bring a Paragraph IV challenge?

No. The case was not a conventional Paragraph IV action.

Paragraph IV certifications apply to abbreviated new drug applications under the Hatch-Waxman Act. CT-P13 was a biologic product regulated through the BPCIA pathway. Celltrion’s action was a declaratory-judgment complaint, not a Paragraph IV certification dispute under the Federal Food, Drug, and Cosmetic Act.

The procedural difference affected both jurisdiction and litigation timing. Under the BPCIA, the reference-product sponsor and biosimilar applicant exchange patent information after the biosimilar application is accepted for review. The statute also provides a 180-day commercial-marketing notice mechanism. At the time of the Celltrion complaint, the scope and timing of those BPCIA procedures remained subject to significant litigation and regulatory uncertainty.

What was the impact on Inflectra’s FDA approval?

The dismissal did not prevent FDA approval of Inflectra. The FDA approved Inflectra on April 5, 2016, as the first U.S. biosimilar to Remicade. The FDA found Inflectra biosimilar to infliximab, with approved uses including several inflammatory and autoimmune diseases.

FDA milestone	Date
Remicade U.S. approval	August 1998
Celltrion declaratory-judgment case filed	2014
Inflectra FDA approval	April 5, 2016
Reference-product 12-year exclusivity period	Generally expired in 2018
U.S. patent period associated with U.S. Patent No. 6,284,471	Generally expired in 2018

FDA biosimilarity approval did not itself resolve patent infringement. The agency determines biosimilarity, safety, purity, and potency. Patent rights remain matters for federal courts.

Inflectra entered a market in which Janssen had already established Remicade as a major immunology product. Celltrion’s product was later joined by other infliximab biosimilars, including Renflexis and Ixifi.

What patent litigation affected the U.S. launch of infliximab biosimilars?

The Celltrion case was one part of the broader Remicade biosimilar patent dispute. The most commercially significant litigation involved Janssen’s efforts to enforce method-of-treatment patents against biosimilar manufacturers and the manufacturers’ attempts to launch around those patents.

Formulation and manufacturing patents

The dispute did not produce a final ruling on a formulation patent or manufacturing-process patent. The principal risk in the case was the asserted antibody and treatment patent estate surrounding infliximab.

For infliximab biosimilars, relevant patent risks generally fell into four categories:

• Composition-of-matter and antibody patents.
• Cell-line and production-process patents.
• Formulation and stability patents.
• Method-of-treatment patents covering specific disease indications or dosing regimens.

The Celltrion docket did not establish that Janssen obtained an enforceable injunction against CT-P13 based on any of these categories.

Method-of-use patents

Method-of-use patents presented the most important post-approval risk for biosimilar manufacturers. A biosimilar may be approved for multiple indications while attempting to omit patented indications through a partial label or “skinny label” strategy.

That strategy can reduce infringement exposure but does not eliminate risk. Physicians may prescribe the product for a patented use, and the reference-product sponsor may argue that the biosimilar manufacturer encouraged or induced infringement through promotional materials, labeling, contracting, or market conduct.

The Celltrion case itself did not decide induced infringement, divided infringement, label carve-outs, or the enforceability of any later-issued method-of-use patent.

Did Janssen and Celltrion reach a settlement?

The reported disposition of 1:14-cv-11613 was dismissal rather than a merits judgment. The public case record does not show that the court issued a patent settlement judgment, injunction, or damages award against Celltrion.

The dismissal should not be treated as evidence that Janssen’s patent was invalid. It also should not be treated as a finding that Celltrion’s product was noninfringing. The court never reached those questions.

Celltrion’s eventual commercial presence in the United States resulted from the FDA approval and subsequent commercial and regulatory arrangements, not from a merits victory in this case.

How strong was Janssen’s Remicade patent estate?

The estate was commercially significant but legally fragmented.

Estate component	Commercial relevance	Result in this case
Core anti-TNF antibody patent	Protected foundational infliximab technology	No merits ruling
Treatment-method patents	Covered selected diseases and dosing uses	No merits ruling
Formulation patents	Could affect stability and product presentation	Not adjudicated
Manufacturing patents	Could affect biosimilar production methods	Not adjudicated
Regulatory exclusivity	Delayed biosimilar reliance and approval	Expired under BPCIA timeline
Trademark and product brand	Protected Remicade branding	Outside the case’s patent merits

The age of the core patent reduced long-term exclusivity value by the time CT-P13 reached the U.S. market. Janssen’s remaining leverage depended more on indication-specific patents, launch timing, contracting, reimbursement, and litigation strategy than on a single foundational patent.

Which companies challenged Remicade exclusivity?

The U.S. infliximab competitive field included Celltrion, Pfizer, and Samsung Bioepis.

Company	Product	Relationship to Remicade
Celltrion	Inflectra	First U.S. infliximab biosimilar
Pfizer	Inflectra commercialization partner in the U.S.	Commercialized Celltrion product
Samsung Bioepis	Renflexis	Competing infliximab biosimilar
Janssen Biotech	Remicade	Reference-product sponsor

The principal competitive challenge was not a small-molecule generic launch. It was a biosimilar entry strategy requiring manufacturing comparability, FDA approval, interchangeability considerations, payer access, and management of patent and contracting barriers.

What generic or biosimilar entry risks existed after dismissal?

The case reduced neither the regulatory burden nor the commercial risks facing Celltrion. It removed one litigation vehicle but left several issues unresolved:

• Janssen could pursue later infringement litigation after a concrete launch threat arose.
• Method-of-use patents could support claims based on label language or induced infringement.
• A biosimilar applicant could face state and federal commercial barriers even after FDA approval.
• Payer formularies and rebates could delay substitution.
• Physician prescribing behavior could limit early market share.
• Patent risk could vary by indication and by jurisdiction.

The dismissal was therefore procedurally favorable to Janssen in the narrow sense that Celltrion’s pre-launch declaratory action failed. It was not a final adjudication of the broader Remicade patent estate.

What is the current legal significance of the case?

Celltrion Healthcare v. Janssen is primarily a case about declaratory-judgment timing in the biosimilar context. Its business significance lies in the limits of pre-launch patent litigation before a biosimilar applicant has created a sufficiently immediate controversy.

The case demonstrates that a biosimilar manufacturer may not obtain an early federal ruling merely by alleging an intent to seek approval and launch. The applicant must establish a concrete dispute tied to regulatory status, infringement exposure, or an imminent commercial act.

The case has limited value for determining whether U.S. Patent No. 6,284,471 was valid or infringed. Because the court did not reach those issues, parties evaluating Remicade-related patent risk must examine the later patent record, subsequent litigation, patent expiration dates, and product-specific launch conduct.

Key Takeaways

• Celltrion sued Janssen in the District of Massachusetts over CT-P13, the proposed infliximab biosimilar later marketed as Inflectra.
• The principal patent was U.S. Patent No. 6,284,471.
• The court dismissed the case for lack of a sufficiently immediate controversy.
• The dismissal was not a ruling that the patent was valid, invalid, infringed, or noninfringed.
• The case was not a Paragraph IV action because Inflectra proceeded under the BPCIA biologic pathway.
• Inflectra received FDA approval on April 5, 2016.
• The litigation did not produce an injunction, damages award, or merits settlement judgment.
• The case’s primary precedent concerns pre-launch declaratory-judgment jurisdiction in biosimilar patent disputes.
• Later commercial risk centered on method-of-use patents, launch conduct, contracting, payer access, and indication-specific patent exposure.

FAQs About Celltrion Healthcare v. Janssen Biotech

Did Celltrion win the patent case against Janssen?

No. The case was dismissed before the court decided patent validity or infringement. Celltrion therefore did not obtain a merits judgment.

Was Inflectra delayed by the 1:14-cv-11613 litigation?

The dismissal itself did not impose an injunction or launch prohibition. The FDA approved Inflectra in April 2016.

Did Janssen sue Celltrion for damages in this case?

The case did not result in a damages judgment. Its disposition was dismissal of Celltrion’s declaratory-judgment action.

Does the case invalidate Remicade patents?

No. The court did not invalidate U.S. Patent No. 6,284,471 or any other Remicade patent.

Was U.S. Patent No. 6,284,471 listed in the Orange Book?

No. Remicade is a biologic, so its patent framework is governed by the BPCIA rather than the Orange Book Paragraph IV system.

References

1. Celltrion Healthcare Co., Ltd. v. Janssen Biotech, Inc., No. 1:14-cv-11613, U.S. District Court for the District of Massachusetts, docket record.

2. Food and Drug Administration. (2016, April 5). FDA approves Inflectra, a biosimilar to Remicade. U.S. Department of Health and Human Services.

3. Food and Drug Administration. (2024). Purple Book: Database of licensed biological products. U.S. Department of Health and Human Services.

4. Biologics Price Competition and Innovation Act of 2009, Pub. L. No. 111-148, §§ 7001-7002, 124 Stat. 119, 804-821 (2010).

5. U.S. Patent No. 6,284,471. (2001). Methods of treating diseases using anti-TNF antibodies. U.S. Patent and Trademark Office.